Mediation analysis of hsCRP in the association between MetS and aICAS in the total sample and the subgroup
| Group | Total effect | Indirect effect | Direct effect | Proportion mediated, % | |||
| Coefficient (95% CI) | P value | Coefficient (95% CI) | P value | Coefficient (95% CI) | P value | ||
| The entire cohort* | 0.030 (0.007–0.050) | 0.012 | 0.002 (−0.000–0.010) | 0.126 | 0.027 (0.005–0.050) | 0.024 | 8.10% |
| ≤65 s† | 0.029 (0.007–0.050) | 0.016 | 0.004 (0.000–0.010) | 0.044 | 0.026 (0.003–0.050) | 0.026 | 12.10% |
| >65 s‡ | 0.053 (−0.057–0.160) | 0.380 | −0.001 (−0.014–0.010) | 0.840 | 0.054 (−0.053–0.160) | 0.360 | 1.30% |
The relationship between MetS (X) and hsCRP (Y): multivariable-adjusted linear regression analysis demonstrated a significant association between MetS and hsCRP in the overall sample (β=0.45, 95% CI: 0.32 to 0.59, p<0.001) and the ≤65 years subgroup (β=0.59, 95% CI: 0.45 to 0.73, p<0.001). No significant association was observed in the >65 years subgroup in the univariable linear regression model (β=0.27, 95% CI: −0.18–0.72, p=0.249).
*The entire cohort: adjusted for sex, age, coronary artery heart disease, MHR and NLR.
†The subgroup aged ≤65 years: adjusted for sex and coronary artery heart disease.
‡The subgroup aged >65 years: adjusted for sex and MHR.
aICAS, asymptomatic intracranial arterial stenos; hsCRP, high-sensitivity C reactive protein; MetS, metabolic syndrome; MHR, monocyte-to-high-density lipoprotein-cholesterol ratio; NLR, neutrophil-lymphocyte ratio.